Email: intake@infuseone.com | Phone: 1-800-581-0645 | Please refer to website www.infuseone.com for location specific fax numbers



Prolastin-C (alpha1proteinase inhibitor, human) Infusion Orders

Patient Name:	DOB:			Male
Diagnosis (please provide ICD10 code)				
□ NKDA Allergies:				
☐ New Start Therapy ☐ Continuation of T	Therapy Date o	Date of last dose (if applicable):		
Ordering Provider:				
Provider NPI:	Dlagage			
	Phone:		Fax:	
Practice Address:	City:		State:	Zip Code:
PREMEDICATIONS			REQUIRED LABS	
☐ Acetaminophen 1000mg PO ☐ Solu-Medrol 125	5mg IVP	V	_	Notes, Labs, Tests supporting
☐ Diphenhydramine 25mg PO ☐ Solu-Cortef 100r	mg IVP		primary diagnosis (please attach)	
☐ Cetirizine 10mg PO ☐ Diphenhydramin	ne 25mg IVP	Ø	Most recent PFTs including FEV1, AAT	
			• •	notype Lab Report, AAT level
PROLASTIN ORDERS			and most recent of	chest X Ray (please attach all)
DOSING:				
☐ Dosage: 60 mg/kg (+/- 10%) IV weekly				
Rate: As tolerated by patient up to 0.08 mL/kg/m	in (in no less than 15 m	inute	es) IV infusion using	15 micron in-line filter
Other:				
FREQUENCY:		REFILLS:		
☑ Intravenous infusion every 1 week				
Other:		(if not indicated prescription will expire one year from date signed)		
Infuse One Standing Orders:				
Provide treatment under Infuse One's Clinical Guidel and Action Plan for Infusion Reactions.	ines, Medication Safety Pr	otoco	l, Emergency Guidelir	nes,
and Action Figure 101 midsion reactions.				
Provider Name				
Provider Signature			Date	

Severe hypersensitivity and anaphylactic reactions may occur in IgA deficient patients with antibodies against IgA. Discontinue administration of the product and initiate appropriate emergency treatment if hypersensitivity reactions occur. Because Prolastin-C is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant CreutzfeldtJakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.